ArticleFrontiers in pharmacology2026
Predicting affinity and potency of new psychoactive substances at cannabinoid 1 receptor with explainable artificial intelligence.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Binding affinity and functional potency are two distinct but pharmacologically related properties in ligand-receptor interactions. The molecular features influencing these two endpoints may differ, reflecting distinct physicochemical and conformational requirements for receptor binding and activation. Consequently, understanding the molecular features that determine both endpoints is essential, especially for the regulation of fast-moving markets of recreational drugs such as new psychoactive substances (NPS), where manufacturers are able to circumvent the stringent national and international regulations by exploiting loopholes within drug regulation. Synthetic cannabinoid receptor agonists form one class of NPS and are generally full agonists of the cannabinoid 1 receptor (CB1). Methods: We compiled publicly available data on CB1 affinity and potency. We used molecular descriptors and fingerprints to train five machine learning (ML) classification models. Using explainable Artificial Intelligence, particularly SHAP values, we analyzed the features driving affinity and potency. Results: Especially XGBoost (XGB) and Random Forest (RF) with molecular descriptors and Extended Connectivity Fingerprints (ECFP), respectively, outperformed the other models in predicting binding affinity. For potency, XGB and RF showed excellent performance with either molecular descriptors or ECFP. All these models had recall, precision, and F1 scores >90%. Further, we mapped SHAP values to selected NPS to highlight structural features having a positive or negative impact on high affinity and potency. Discussion: Affinity relies mainly on lipophilicity and membrane-partitioning descriptors, whereas potency depends on a broader combination of lipophilicity, shape, branching, and electronic descriptors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.